Rhythm shares surge 10.16% intraday as EMA's CHMP adopts positive opinion for expanded use of IMCIVREE® in hypothalamic obesity.

Rhythm surged 10.16% intraday, as the company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the expansion of the marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and appetite control in adults and children over 4 years old with acquired hypothalamic obesity due to hypothalamic injury or dysfunction.